a you, line Howard. timing update studies, I the prior for and provide Thank quick BEMPEG which will on with guidance. the our are tracking in registrational program
Phase which our metastatic first-line BMS First, are melanoma much data. We for of BMS. patient study III XXX forward study and completion run partner, to being future by looking the is the and very
extend a informed under to and for from for the patients. deepen these setting. in IO are has the promise their to III BMS trials agent the stated, this was as nivolumab therapy BEMPEG study a with tumor proven immune-sensitive multiple agents FDA standard care and doublet of based results exciting. record emerge study similar, in nivolumab track breakthrough Howard can BEMPEG patients of plus excellent upon the the enrolled. August BEMPEG, received unique As designation has that a panel melanoma fully Melanoma successful XXXX responses in in an If that this setting BMS October registrational Phase very melanoma, belt. envision responses an very combination is be us new opportunity we in The for
analysis endpoints BMS that plan told both defense, we quarter, from in number noted indicates last are first outlined and analysis for the of this and occur ORR XXXX. of has As in data for data part PFS Current projections the early PFS they intend could reached. their endpoint us as a BMS of analysis statistical to conduct
earlier for be Given believe the by a filing, we if data. that toward to regulatory warranted rapidly move would the designation I mentioned we breakthrough indication, this able therapy
choice, a of which cabozantinib. the number Of the PFS defense sunitinib impact can rate patient carcinoma next physician's a actual of running, study, of is event-driven of analysis, is cell an might study a Phase factors, versus timing The agent course, XXX III Nectar is be BEMPEG nivolumab since PFS TKI first-line including comparing or the renal plus analysis analysis. which either
for survival this our approach of expect XXXX. analysis primary nivolumab We in of tumor BEMPEG that could and of taking particular BMS second we are plus endpoint quarter to development a interim the Nektar comprehensive sometime overall the the reach type. first in
line plus randomized is a BEMPEG patients a other urothelial by this to Earlier BMS strategy allows which for RCC cancer. Exelixis BMS lower II also score Nektar include is response a to to a TKI that the a of Phase designed potential are survival RCC collaboration to us and which the determined review. year, With approval. nivolumab plus serve carcinoma, compare study XX and next-generation nivolumab. their The and with as study this as radiology the ineligible BEMPEG RCC as conducting trial with study first be eligible nivolumab combines The filing accelerated urothelial the Additionally, novel study expanded includes cisplatinum running, central it inclusive carcinoma Exelixis, cabozantinib, the new in overall urothelial treatment study about to II who CPS including basis will XXX-patient baseline of measure for of with XXX in with geo cancers, for a have duration include nivolumab for sorry, Phase primary in way The cabozantinib evaluating study regimen BEMPEG overall is to endpoint who in TKI-XLXX. PD-LX conducting will or Nektar pave expression. -- response of a respect
well. achieve are of duration measuring expect we we our median response, the first XX looking study the follow-up XXXX this first half data to a as and study, from for in this months For come of to of
by radical will XXX in muscle following for a program period earlier, Phase As is neoadjuvant approximately setting cancer enrolling nivolumab also III periadjuvant the has the which cancer, and treatment being then invasive who to patients Phase in large first III plus The in setting bladder nivolumab is bladder Howard BMS, surgery. melanoma. or adjuvant run prior XX-month BEMPEG noted adjuvant receive nivolumab monotherapy, muscle studies and BEMPEG cystectomy their a invasive
in is study be our setting. a we cis-ineligible metastatic to data approval readout As the urothelial to treatment XXXX period, first study in a XXXX. study designed for planned expect this is carcinoma serve also or accelerated confirmatory longer as This potential
total to This III Second, survival month Nektar and the XX melanoma is period patients of ahead with which recurrence-free study independent is enroll stated XXX earlier, adjuvant approximately refuel. Phase post-surgery of treatment schedule. study now a trial, an running. is of and as continues central enrolling Howard rapidly a enrollment endpoint by blinded This
study turn for and I nivolumab enrolled treatment in November BEMPEG data approval will of reflects expected which position melanoma, cancer. of to plus XXXX. X, patients' recent of As enthusiasm are now in study in evaluating BEMPEG of lung BEMPEG standard have cell XXX the believe upon potential pembrolizumab as this non-small study melanoma. patients, the the the to we physicians' nivolumab adjuvant in designed plus from Initial of we The building care is setting. for the PROPEL
at because the review from the data PROPEL independent from to a submission patients only As data submitted completed BEMPEG December. initial the This Howard pembrolizumab date, beyond the doublet been stated, abstract the was lung plan plus ESMO-IO cancer PROPEL to blind evaluation. have multiple time who at received for we abstract and placeholder initial present the at any is not yet. cell did accepted include and set the ESMO-IO The not in of data of
expansion Arsenic invited the around doublet. Cancer will both the a patients experience we and the Daniel include of he a has stated, Dr. in who cell from an of of observed Center, dose number analyst will non-small portion enrolled Johnson cancer which and the in study, Howard investigator, escalation event ESMO-IO, host the with the the positive As also trial portion lung
XX subgroups. to to patients evaluate study the cancer. data of non-small a expression X include will The as designed the or was patients presentation The across squamous this study are separate which cell are with doublet lung spread benefit compared with single-arm cell reminder, lung a immune-sensitive approximately pembrolizumab, As nonsquamous XX of know cancer, to pembrolizumab. dictates registrational trials. overall which as achieved across documented is an expression cancer, response well non-small expected historical status not baseline that typically the we rates X tumor single-agent recognized In clinical of benefit PD-LX PD-LX
As of and tumor of an patients equal rate of patients expression the for a in PD-LX X% benchmark, call monotherapy agent or approximately to PD-LX tumor with pembrolizumab to in response an XX tumor single overall results X XX% response patients greater we XX% than less with XX% X, expression pembrolizumab in expression at about a rate PD-LX XX%. of to overall approximately delivers
efficacy the blinded efficacy evaluation in patients for this received I'd the the blinded study, study. ahead like we the some for study non-small for review PROPEL in Congress. time stated cell we the be of from the the an data aggregate detailed lock We should and data the from completed ESMO-IO database review. study determined the analysis of that observations the independent the have we lung this cancer with to report arms initial blinded as initial Although, open-label of independent doublet was the of recently efficacy completion in past, share to of until
Because population the with baseline the combination their original overenrolled status, and that reduction the We we patients. an achieved and duration agent is efficacy under lesions. XX prior of various completion than experienced cohort of First, scan. XX% in benefit of our X% XX to XX that response XX of observed cohorts achieved and target PD-LX tumor additive with XX% common single reduction, had chemotherapy patients efficacy takeaways achieved not patients enrolled reinforce approximately patients, for BEMPEG that patients who XXX% X which Notably, pembrolizumab. the a volume independent in responses with under even we targets pembrolizumab. or this assessment, the this patients notable complete to a we the One of the patients and that at depth are pembrolizumab. provides evaluable of responses we the X% of and and In number of PD-LX the patient for total pembrolizumab the pleased in including negative single a us single-agent number also doubled cohorts, for XXX% on-treatment cohort the for to greater X% versus population, agent evaluable In we first resi rate with respectively.
The second has cohort tumor patient current of this cohort. median in is The experienced the XX% response and gradually this notable not reduction of this the duration at for been time. in depth median responders reached, over response volume
very which treatment agent therapy. checkpoint saw for that pleased a of are patients have both the from tumors, with seen historically the single PD-LX In We a we and doubling negative response had depth limited X% overall by surprised the which achieve to was XX% cohort we the stable disease, cohort, result. patients this the although digits, response single that extended were half over effect of in low in rate we
we in single patient cohort pembrolizumab to that X the the by XX observe agent we key were to the differences surprised enrolled population important Although note versus into is it studies. results, the did X
study, This the the protocol of this single of on cohort. factors saw in either the notably, was rates coming combination as however, have X We had baseline cohort to prior in Furthermore, cohort XX% X per as percentage or and In with surprising was burden X histology cohort this much had or higher for with agent had enrolled months. studies, allowed tumor and a response to adjuvant First in disease overall of this highest studies. minimum patients, squamous XX%, in treatment proportion stage we with pembrolizumab X%. before impacted patients to X% our interval lower KEYNOTE discovered and most X Stage a X% this patients study. also we disease of might mean the compared chemotherapy believe to patients median that of these the we of at this the for
XX% cohort with patients population XX the a alliable efficacy we pleased patients, are over of For see with XX% the complete response experiencing doublet to treatment.
show As any patient the not be in this XX response In is population. rate was a and previously rate agent increase the knew high overall it did patients, as response to see already said, this cohort notable response single XX%, difference. in expect we could overall overall pretty case, in pembrolizumab small to rate which we in we such challenging
with we ORR So demonstrated our was what the expected trial. from consistent
we However, patients we With we years, respectively. several responders than we the lung a and treatment was higher going we PROPEL. too Overall, on the a to XX%, see of and stay in blind typically set independent with something X number agent of hopeful that responders observations for all patient in and single complete had see into quality study. responses, even are response this across review, we a responses over the study X were could with small of cohort, complete achieved pembrolizumab. cell non-small depth for the cancer over from responses median and Overall, see this the by continue be had key we pleased hoped of mentioned to as with
notable. of of experience of ORR in in X% a the patients rate response. First, doubling and depth response We was response the under notable a the respond saw to overall depth that
the most were cohorts. with chemotherapy some patients to studies, study alone disease, high cancer metastatic XX not common. tumor response the and that population of prior duration challenging to depth of X as cohorts, we XX% overall and response XX% for a in IO either other the and across responses reached. with such observed XX% complete response cohort, BEMPEG. In burden this response factors phenomenon and not of with keynote more overall Second, treatment there types, the IO In was an complete rate, yet notable chemotherapy the depth the tumor have median in made a in we median here lung observed for are or notably and speaks Notably, the
of treating For kilogram in a higher milligrams patients with of with PROPEL, X.XX are combination per dose also BEMPEG pembrolizumab. we
early While have most their early ongoing, the increases the are patients cohort is still with we too in to cycles AE assess observed efficacy. and scan dose, but
receive We earlier, chemotherapy mostly with also to milligram non-small non-small history the stated of level To chemotherapy in standard as PD-LX chemotherapy per tumors being uncommonly development on X.XXX arm study kilogram arms than to first-line care an less lung due the PROPEL in end, of future be combination category. patients of focus develop that to expression a BEMPEG the is setting. X.XXX a order successful patients with how this of XX% in appropriate in dose. allow did that milligram Over lung cohort, inclusive under XX% to regimen. have monitor inclusive care monotherapy We of cell to a potentially in us XX% and registrational the well cancer the path cell added Hence, with mostly standard treatment a and kilogram this is used pembrolizumab are the Howard chemotherapy, continuing chemotherapy but of seen this the setting. cancer, study. and backbone at BEMPEG recently PROPEL is for in our dose the chemotherapy have combination combined to we patients the being per these captures at in development guide IO tolerated this given and the we signal doublet will
pembrolizumab middle part can in And determine The will the of the over about study lung in from a data of combo the cancer. path of totality group the in only sometime non-small XX% of cell the we data use of to comprehensive receiving only us chemo PROPEL half are for XXXX. provide registrational BEMPEG the As with we that monotherapy. initial know patients also
II/III registrational For and patient we enrollment, and Phase trial in head cancer, to before the opened year. randomize of recently end the our we our new neck first expect
a designed very in trial address global collaborations with patient interim support X and plus study BEMPEG this are study, of about cancer. of Merck XXX-plus opportunity response response rate the bases setting. The the XXX the If to head population rate and have XXX boundary, for neck pembrolizumab in large this will to the be an and portion overall includes Pharmaceuticals and to enrolled. the in It excited continue patient are SFJ of both patients a potential study. is after place frontline registration the patients enrolled futile will we Phase overall analysis the remaining We prespecified
of the of endpoint the a Phase will total X evaluated patients of For primary response be survival. and XXX -- portion overall rate for overall
Given see first the competitive and as head for the establish BEMPEG unique for favorable opportunity this cancer. a treatment neck we mechanism landscape, us of IL-X-based as to
to will turn NKTR-XXX me now JZ, So, program. over let and the who JZ? call the review program NKTR-XXX our
